Elisa Agostinetto: Estradiol levels remain the biomarker of choice
Jan 28, 2024, 18:29

Elisa Agostinetto: Estradiol levels remain the biomarker of choice

Elisa Agostinetto, Clinical Research Fellow at the Institute Jules Bordet, recently shared on X/Twitter:

“Out in npj Journals Breast a nice review on the selection of appropriate biomarkers to monitor the effectiveness of ovarian function suppression with GnRH agonists in ER+.

Estradiol levels remain the biomarker of choice.”

Read further.

Source: Elisa Agostinetto/X